Rigel Pharmaceuticals, Inc.
RIGL
$42.58
$1.794.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.21% | 47.48% | 64.00% | 79.24% | 105.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.31% | 47.61% | 64.15% | 79.13% | 105.62% |
| Cost of Revenue | 35.57% | 20.36% | 25.91% | 26.91% | 60.04% |
| Gross Profit | -4.06% | 55.78% | 75.86% | 95.49% | 119.92% |
| SG&A Expenses | 7.65% | 5.80% | 2.51% | 4.56% | 4.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.16% | 10.08% | 8.85% | 10.24% | 17.24% |
| Operating Income | -16.77% | 183.58% | 418.63% | 1,151.72% | 1,259.76% |
| Income Before Tax | -13.68% | 219.94% | 563.33% | 2,846.02% | 796.57% |
| Income Tax Expenses | -18,072.09% | -25,708.77% | -27,931.67% | -- | -- |
| Earnings from Continuing Operations | 229.08% | 879.70% | 1,999.08% | 2,819.35% | 787.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 229.08% | 879.70% | 1,999.08% | 2,819.35% | 787.33% |
| EBIT | -16.77% | 183.58% | 418.63% | 1,151.72% | 1,259.76% |
| EBITDA | -16.18% | 173.90% | 384.03% | 962.78% | 1,542.22% |
| EPS Basic | 221.64% | 854.73% | 1,947.01% | 2,798.08% | 775.29% |
| Normalized Basic EPS | -15.89% | 213.80% | 552.52% | 2,825.48% | 784.42% |
| EPS Diluted | 201.91% | 805.76% | 1,856.73% | 2,814.65% | 760.73% |
| Normalized Diluted EPS | -20.04% | 205.12% | 539.26% | 2,773.19% | 774.34% |
| Average Basic Shares Outstanding | 3.18% | 2.75% | 2.31% | 1.81% | 1.43% |
| Average Diluted Shares Outstanding | 8.67% | 7.63% | 6.47% | 4.72% | 2.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |